Skip to main content
Premium Trial:

Request an Annual Quote

Jeffrey Williams, Dennis Langer

Premium

Jeffrey Williams has been named CEO of HandyLab, which develops clinical diagnostic products. He comes to HandyLab from Genomic Solutions, where he was a co-founder and CEO until its acquisition by Harvard Biosciences in 2002, and where he subsequently headed up the Genomic Solutions unit.

Prior to co-founding Genomic Solutions, Williams served as chief operating officer of International Remote Imaging Systems, which specialized in digital imaging for the clinical diagnostic and research markets. He also held the position of vice president and global business manager for clinical diagnostics at Boehringer Mannheim, now part of Hoffman LaRoche, and held positions at the Organon Pharmaceutical division of Akzo Nobel.


Myriad Genetics has appointed Dennis Langer to its board of directors. Langer, who will begin his position on May 1, is president of Dr. Reddy’s Laboratories. Before coming to Dr. Reddy’s, he was senior vice president for R&D project and portfolio management at GlaxoSmithKline.

Langer has a JD from Harvard Law School, an MD from Georgetown University School of Medicine, and a BA in biology from Columbia University. He currently serves on the board of Transkaryotic Therapies, and on the boards of visitors at Columbia University, and Georgetown University School of Medicine.

 

Filed under

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.